


**Product Name** : CFI-400945  
**Cat. No.** : PC-42963  
**CAS No.** : 1338806-73-7  
**Molecular Formula** : C<sub>33</sub>H<sub>34</sub>N<sub>4</sub>O<sub>3</sub>  
**Molecular Weight** : 534.6481  
**Target** : Polo-like Kinase (PLK)  
**Solubility** : DMSO: ≥ 166.66 mg/mL



## Biological Activity

CFI-400945 (Ocifisertib) is a potent, highly selective **PLK4** inhibitor with  $K_i$  of 0.26 nM and  $IC_{50}$  of 2.8 nM, does not significantly inhibit PLK1/2/3 at 50  $\mu$ M.

CFI-400945 causes dysregulated centriole duplication, mitotic defects, and cell death in multiple cancer cell lines (A549  $GI_{50}$ =5 nM, OVCAR-3  $GI_{50}$ =18 nM).

CFI-400945 significantly inhibits human cancer xenografts.

CFI-400945 causes polyploidy, growth inhibition, and apoptotic death of murine and human lung cancer cells, despite expression of mutated KRAS or p53, produces supernumerary centrosomes and mitotic defects in lung cancer cells.

## References

Sampson PB, et al. *J Med Chem.* 2015 Jan 8;58(1):147-69.

Mason JM, et al. *Cancer Cell.* 2014 Aug 11;26(2):163-76.

Lohse I, et al. *Oncotarget.* 2017 Jan 10;8(2):3064-3071.

Kawakami M, et al. *Proc Natl Acad Sci U S A.* 2018 Feb 20;115(8):1913-1918.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com